ATE234099T1 - Immununterdrückende effekte von 8 substituierten xanthinderivaten - Google Patents

Immununterdrückende effekte von 8 substituierten xanthinderivaten

Info

Publication number: ATE234099T1
Authority: AT; Austria
Prior art keywords: substituted; carbon atoms; unsubstituted; phenyl; group
Prior art date: 1998-04-24

Application number

AT98201323T

Other languages

English (en)

Inventor

Mark Jozef Albert Waer

Piet Andre Maurits M Herdewijn

Wolfgang Pfleiderer

Original Assignee

Leuven K U Res & Dev

Wolfgang Pfleiderer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-24

Filing date

1998-04-24

Publication date

2003-03-15

1998-04-24 Application filed by Leuven K U Res & Dev, Wolfgang Pfleiderer filed Critical Leuven K U Res & Dev

2003-03-15 Application granted granted Critical

2003-03-15 Publication of ATE234099T1 publication Critical patent/ATE234099T1/de

Links

LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 3
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title abstract 2
230000000694 effects Effects 0.000 title 1
230000006028 immune-suppresssive effect Effects 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 abstract 5
125000001931 aliphatic group Chemical group 0.000 abstract 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003277 amino group Chemical group 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
-1 N-substituted sulfonamide Chemical class 0.000 abstract 1
ABDMQSFNJPYOLA-UHFFFAOYSA-N NS(=O)(=O)[N+]([O-])=O Chemical class NS(=O)(=O)[N+]([O-])=O ABDMQSFNJPYOLA-UHFFFAOYSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
125000004103 aminoalkyl group Chemical group 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001033 ether group Chemical group 0.000 abstract 1
125000000524 functional group Chemical group 0.000 abstract 1
125000002541 furyl group Chemical group 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229920006395 saturated elastomer Chemical group 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT98201323T 1998-04-24 1998-04-24 Immununterdrückende effekte von 8 substituierten xanthinderivaten ATE234099T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98201323A EP0956855B1 (de)	1998-04-24	1998-04-24	Immununterdrückende Effekte von 8 substituierten Xanthinderivaten

Publications (1)

Publication Number	Publication Date
ATE234099T1 true ATE234099T1 (de)	2003-03-15

Family

ID=8233642

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98201323T ATE234099T1 (de)	1998-04-24	1998-04-24	Immununterdrückende effekte von 8 substituierten xanthinderivaten

Country Status (5)

Country	Link
EP (1)	EP0956855B1 (de)
AT (1)	ATE234099T1 (de)
DE (1)	DE69812070T2 (de)
DK (1)	DK0956855T3 (de)
ES (1)	ES2189079T3 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7276506B2 (en)	1998-12-28	2007-10-02	4 Aza Bioscience Nv	Immunosuppressive effects of pteridine derivatives
WO2000039129A1 (en) *	1998-12-28	2000-07-06	K.U. Leuven Research & Development	Immunosuppressive effects of pteridine derivatives
US7304070B2 (en)	2001-11-09	2007-12-04	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
US7125993B2 (en) *	2001-11-09	2006-10-24	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
US7317017B2 (en)	2002-11-08	2008-01-08	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
KR100937620B1 (ko)	2001-11-09	2010-01-20	씨브이 쎄러퓨틱스, 인코포레이티드	Ａ２ｂ 아데노신 수용체 길항제
CA2443023A1 (en)	2002-02-01	2003-08-07	King Pharmaceuticals Research And Development, Inc.	8-heteroaryl xanthine adenosine a2b receptor antagonists
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
US7279576B2 (en)	2002-12-31	2007-10-09	Deciphera Pharmaceuticals, Llc	Anti-cancer medicaments
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
CN100361992C (zh) *	2003-02-19	2008-01-16	霍夫曼-拉罗奇有限公司	用作pepck抑制剂的磺酰胺取代的黄嘌呤
DE60322748D1 (de) *	2003-05-06	2008-09-18	Cv Therapeutics Inc	Xanthinderivate als a2b-adenosinrezeptorantagonisten
AU2011202523B2 (en) *	2003-11-21	2013-05-30	Gilead Sciences, Inc.	A2B adenosine receptor antagonists
WO2006071940A2 (en)	2004-12-23	2006-07-06	Deciphera Pharmaceuticals, Llc	Enzyme modulators and treatments
US10144736B2 (en)	2006-07-20	2018-12-04	Gilead Sciences, Inc.	Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009078A2 (en)	2006-07-20	2008-01-24	Gilead Sciences, Inc.	4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8188113B2 (en)	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en)	2006-10-11	2010-09-07	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CA2684950A1 (en)	2007-04-20	2008-10-30	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US8871751B2 (en)	2008-01-18	2014-10-28	The Board Of Trustees Of The University Of Illinois	Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
CN102256493A (zh)	2008-10-29	2011-11-23	迪赛孚尔制药有限公司	表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN107001371B (zh)	2014-10-09	2019-07-05	广东众生睿创生物科技有限公司	羟基嘌呤类化合物及其应用
CN111233863B (zh) *	2014-10-09	2022-10-25	广东众生睿创生物科技有限公司	羟基嘌呤类化合物及其应用
DK3097102T3 (en)	2015-03-04	2018-01-22	Gilead Sciences Inc	TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS
MA46093A (fr)	2016-09-02	2021-05-19	Gilead Sciences Inc	Composés modulateurs du recepteur de type toll
WO2018045150A1 (en)	2016-09-02	2018-03-08	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN110041330B (zh) *	2018-01-16	2020-08-11	新发药业有限公司	一种伊曲茶碱的环保制备方法
AU2019216351B2 (en)	2018-01-31	2024-07-25	Deciphera Pharmaceuticals, Llc	Combination therapy for the treatment of mastocytosis
EP3746059B1 (de)	2018-01-31	2026-03-04	Deciphera Pharmaceuticals, LLC	Kombinationstherapie zur behandlung von gastrointestinalen stromatumoren
WO2020185812A1 (en)	2019-03-11	2020-09-17	Teva Pharmaceuticals International Gmbh	Solid state forms of ripretinib
TW202210480A (zh)	2019-04-17	2022-03-16	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202212339A (zh)	2019-04-17	2022-04-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TWI879779B (zh)	2019-06-28	2025-04-11	美商基利科學股份有限公司	類鐸受體調節劑化合物的製備方法
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
FI4013412T3 (fi)	2019-08-12	2026-03-24	Deciphera Pharmaceuticals Llc	Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
CN110922363A (zh) *	2019-12-28	2020-03-27	新华制药（寿光）有限公司	一种紫脲酸连续化生产工艺
PL4084779T3 (pl)	2019-12-30	2025-02-24	Deciphera Pharmaceuticals, Llc	Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en)	2019-12-30	2023-08-31	Deciphera Pharmaceuticals, Llc	Amorphous kinase inhibitor formulations and methods of use thereof
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0490181A1 (de) *	1990-11-30	1992-06-17	Hoechst-Roussel Pharmaceuticals Incorporated	Verwendung von Xanthinen zur Herstellung eines Medikaments mit immunsuppressiver Wirkung
CA2218548A1 (en) *	1995-05-19	1996-11-21	Chiroscience Limited	Xanthines and their therapeutic use

1998
- 1998-04-24 ES ES98201323T patent/ES2189079T3/es not_active Expired - Lifetime
- 1998-04-24 AT AT98201323T patent/ATE234099T1/de not_active IP Right Cessation
- 1998-04-24 EP EP98201323A patent/EP0956855B1/de not_active Expired - Lifetime
- 1998-04-24 DE DE69812070T patent/DE69812070T2/de not_active Expired - Fee Related
- 1998-04-24 DK DK98201323T patent/DK0956855T3/da active

Also Published As

Publication number	Publication date
ES2189079T3 (es)	2003-07-01
DK0956855T3 (da)	2003-07-14
EP0956855A1 (de)	1999-11-17
EP0956855B1 (de)	2003-03-12
DE69812070T2 (de)	2003-12-11
DE69812070D1 (de)	2003-04-17

Legal Events

Date

Code

Title

Description

2003-09-15

UEP

Publication of translation of european patent specification

Ref document number: 0956855

Country of ref document: EP

2009-01-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69812070D1 (de)	2003-04-17	Immununterdrückende Effekte von 8 substituierten Xanthinderivaten
NO933452D0 (no)	1993-09-27	Et terapeutisk middel for parkinson's sykdom
EP1035123A4 (de)	2001-12-12	Neue heterozyklische verbindungen
ATE52498T1 (de)	1990-05-15	Amidderivate.
FI901030A0 (fi)	1990-03-01	Menetelmä valmistaa terapeuttisesti aktiivisia 2-(1-piperatsinyyli)-4-fenyylisykloalkanopyridiinijohdannaisia
ATE282614T1 (de)	2004-12-15	Phenylharnstoff und phenylthioharnstoffderivate
HUT54279A (en)	1991-02-28	Herbicidal and bioregulating compositions comprising salicyl-aldehyde and salicylic acid derivatives and their sulfur analogs, as well as process for producing the active ingredients
PT87063A (pt)	1988-04-01	Heterocyclic compounds and their preparation and use
FR2598709B1 (fr)	1990-08-03	Derives de l'acide quinoleinecarboxylique
NO931317L (no)	1993-10-11	Et terapeutisk middel for parkinson's sykdom
FR2800735B1 (fr)	2002-02-01	Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
DK384485A (da)	1986-02-26	1,6-naphthyridinderivater med kardilaterende virkning
BRPI0408675A (pt)	2006-03-28	derivados de talidomida solúveis em água
EP0726269A4 (de)	1997-01-22	Quinolincarbonsäurederivat une seine salze
KR890009862A (ko)	1989-08-04	N-치환 메르캅토 프로판아미드 유도체
KR910000150A (ko)	1991-01-28	대사성 골 질환 치료제
EP0802179A4 (de)	2000-04-05	Derivate substituierter amidinonaphthylester
HUP0402101A2 (hu)	2005-01-28	Vajsavszármazékok, előállításuk és alkalmazásuk
KR910700236A (ko)	1991-03-14	치환된 3-아자비사이클로[3,1,1]헵탄, 이의 제조방법 및 이의 용도
DE69827706D1 (de)	2004-12-30	5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
DE69026098D1 (de)	1996-04-25	Organogermaniumderivate enthaltende Zubereitungen zur therapeutischen Verwendung